On October 20, HolonIQ unveiled its 2022 list of the top 200 Asian health tech companies poised for innovation. The list is categorized into nine sections: Prevention, Research, Care, Supply Chain, Hardware, Finance, Treatment, Systems, and Diagnosis.
META Pharmaceuticals earned a place in the Research segment due to its pioneering work in the field of immune metabolism. Alongside other notable unicorn companies like Abbot Biologics, Neufos Biologics, and Biotronik, META Pharmaceuticals is making significant strides in advancing therapeutic solutions for autoimmune diseases.
Headquartered in New York City, HolonIQ stands as a world-leading market consulting firm with a laser focus on harnessing its robust analytics capabilities. Our mission? To provide insights and solve complex strategic problems for global impact leaders. Our coverage spans critical areas such as climate, education, and healthcare technology.
META Pharmaceuticals, on the other hand, is at the forefront of groundbreaking research. Leveraging the latest advancements in immuno-metabolic biological theory, we’ve identified a series of novel targets involving metabolic proteases. These targets hold the promise of safely and effectively regulating immune system function. Currently, we’re advancing three first-in-class pipelines, with our core pipeline, Meta-1, slated for clinical study submission in 2023. But our commitment doesn’t end there. META Pharmaceuticals is dedicated to constructing a broad and diverse pipeline, spanning a wider spectrum of metabolic pathways. Our goal? To benefit a multitude of therapeutic indications, including cancer.
The inclusion of META Pharmaceuticals in the HolonIQ list underscores the recognition by leading industry research organizations of the emerging field of immunometabolism. As we continue to delve into immune metabolism, we remain steadfast in our pursuit of innovation. Our mission remains unwavering: to develop superior drugs that will positively impact millions of autoimmune disease patients worldwide.
